KERX
$5.08
Keryx Biopharm
$.15
3.04%
KERX
Earnings Whisper ®
N/A
1st Quarter March 2018
Consensus:  ($0.19)
Revenue:  $28.31 Mil
Wednesday
May 9
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when KERX reports earnings?
Beat
Meet
Miss

Where is KERX's stock price going from here?
Up
Flat
Down
Stock chart of KERX
Analysts
Summary of analysts' recommendations for KERX
Score
Grade
Pivots
Resistance
$5.40
$5.25
$5.17

$5.02

Support
$4.93
$4.78
$4.70
Tweet
Growth
Description
Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.
Peers
CelgeneRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalJohnson & JohnsonZoetisEndo International plcEli LillyMylanPerrigo